S@ ( S@ : Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma ) was an Intergroup phase III trial that enrolled high-risk patients ( stage IIIA-N@a through IIIC-N@ ) , randomly assigning them to receive either HDI or biochemotherapy consisting of dacarbazine , cisplatin , vinblastine , interleukin-@ , IFN alfa-@b ( IFN -- @b ) and granulocyte colony-stimulating factor given every @ days for three cycles .